Skip to main content
SpringerLink
Log in

Tyrosine Kinase Inhibitors in Systemic Mastocytosis

  • Chapter
  • First Online:
Book cover Mastocytosis

  • 471 Accesses

Abstract

The strong association of systemic mastocytosis (SM) with mutations and constitutive activation of the receptor tyrosine kinase KIT in >90% of patients has led to great interest in investigating the clinical activity and safety of tyrosine kinase inhibitors (TKI) in these neoplasms. These agents were (a) either already approved for other hematologic neoplasms and demonstrated in vitro activity toward mutated forms of KIT, for example, imatinib, nilotinib or dasatinib; or (b) applied to patients with SM because of activity against KIT in vitro as part of a broader multikinase inhibitory profile, for example, midostaurin; or c) developed as specific KIT inhibitors, for example, avapritinib, ripretinib, or masitinib. Midostaurin and imatinib have been approved for specific indications by the regulatory health authorities, while avapritinib, ripretinib, and masitinib are still being investigated in clinical trials. Due to the low overall response rates, nilotinib and dasatinib are no longer actively pursued in SM.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alvarez-Twose I, Matito A, Morgado JM, Sanchez-Munoz L, Jara-Acevedo M, Garcia-Montero A, et al. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget. 2017;8(40):68950–63.

    Article  Google Scholar 

  2. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183–8.

    Article  CAS  Google Scholar 

  3. Droogendijk HJ, Kluin-Nelemans HJ, van Doormaal JJ, Oranje AP, van de Loosdrecht AA, van Daele PL. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer. 2006;107(2):345–51.

    Article  CAS  Google Scholar 

  4. Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintas-Cardama A, Luthra R, et al. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481–4.

    Article  CAS  Google Scholar 

  5. Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, et al. Advanced mast cell disease: an Italian hematological multicenter experience. Int J Hematol. 2008;88(5):483–8.

    Article  Google Scholar 

  6. Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362(9383):535–6.

    Article  CAS  Google Scholar 

  7. Lim KH, Pardanani A, Butterfield JH, Li CY, Tefferi A. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol. 2009;84(12):790–4.

    Article  CAS  Google Scholar 

  8. Iurlo A, Gianelli U, Beghini A, Spinelli O, Orofino N, Lazzaroni F, et al. Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. Oncotarget. 2014;5(13):4665–70.

    Article  Google Scholar 

  9. Hoade Y, Metzgeroth G, Schwaab J, Reiter A, Cross NCP. Routine screening for KIT M541L is not warranted in the diagnostic work-up of patients with Hypereosinophilia. Acta Haematol. 2018;139(2):71–3.

    Article  CAS  Google Scholar 

  10. Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, et al. Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Ann Hematol. 2017;96(9):1463–70.

    Article  CAS  Google Scholar 

  11. Metzgeroth G, Schwaab J, Gosenca D, Fabarius A, Haferlach C, Hochhaus A, et al. Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia. 2013;27(11):2254–6.

    Article  CAS  Google Scholar 

  12. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res. 2017;77(6):1261–70.

    Article  CAS  Google Scholar 

  13. Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol. 2017;28(10):2367–76.

    Article  CAS  Google Scholar 

  14. Baird JH, Gotlib J. Clinical validation of KIT inhibition in advanced systemic mastocytosis. Curr Hematol Malig Rep. 2018;13(5):407–16.

    Article  Google Scholar 

  15. Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106(8):2865–70.

    Article  CAS  Google Scholar 

  16. DeAngelo DJ, George TI, Linder A, Langford C, Perkins C, Ma J, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470–8.

    Article  CAS  Google Scholar 

  17. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–41.

    Article  CAS  Google Scholar 

  18. Jawhar M, Schwaab J, Naumann N, Horny HP, Sotlar K, Haferlach T, et al. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood. 2017;130(2):137–45.

    Article  CAS  Google Scholar 

  19. Reiter A, Kluin-Nelemans HC, George T, Akin C, DeAngelo DJ, Hermine O, et al. Pooled survial analysis of midostaurin clinical study data (D2201 + A2213) in patients with advanced systemic mastocytosis (advSM) compared with historical controls. EHA. 2017; abstract S788.

    Google Scholar 

  20. Jawhar M, Schwaab J, Schnittger S, Meggendorfer M, Pfirrmann M, Sotlar K, et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016;30(1):136–43.

    Article  CAS  Google Scholar 

  21. Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny HP, Metzgeroth G, et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015;29(5):1115–22.

    Article  CAS  Google Scholar 

  22. Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122(14):2460–6.

    Article  CAS  Google Scholar 

  23. Damaj G, Joris M, Chandesris O, Hanssens K, Soucie E, Canioni D, et al. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One. 2014;9(1):e85362.

    Article  Google Scholar 

  24. Jawhar M, Schwaab J, Meggendorfer M, Naumann N, Horny HP, Sotlar K, et al. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica. 2017;102(6):1035–43.

    Article  CAS  Google Scholar 

  25. Jawhar M, Dohner K, Kreil S, Schwaab J, Shoumariyeh K, Meggendorfer M, et al. KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia. 2019;33(5):1124–34.

    Article  CAS  Google Scholar 

  26. Radia DH, Deininger MW, Gotlib J, Bose P, Drummond MW, Hexner EO et al. Avapritnib, a potent and selective inhibitor of KIT D816V, induces complete and durable responses in patients with advanced systemic mastocytosis (AdvSM). EHA. 2019; abstract S830.

    Google Scholar 

  27. Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018;103(5):799–809.

    Article  CAS  Google Scholar 

  28. Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, et al. Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PLoS One. 2009;4(9):e7258.

    Article  Google Scholar 

  29. Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am J Hematol. 2010;85(12):921–5.

    Article  CAS  Google Scholar 

  30. Lortholary O, Chandesris MO, Bulai Livideanu C, Paul C, Guillet G, Jassem E, et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet. 2017;389(10069):612–20.

    Article  CAS  Google Scholar 

  31. Hochhaus A, Baccarani M, Giles FJ, le Coutre PD, Muller MC, Reiter A, et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015;141(11):2047–60.

    Article  CAS  Google Scholar 

  32. Verstovsek S, Tefferi A, Cortes J, O'Brien S, Garcia-Manero G, Pardanani A, et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res. 2008;14(12):3906–15.

    Article  CAS  Google Scholar 

  33. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015;100(4):479–88.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany

    Mohamad Jawhar & Andreas Reiter

  2. Division of Hematology, Stanford Cancer Institute, Stanford, CA, USA

    Jason Gotlib

Authors
  1. Mohamad Jawhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Gotlib
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Reiter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Reiter .

Editor information

Editors and Affiliations

  1. Professor of Medicine, Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, MI, USA

    Cem Akin

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Jawhar, M., Gotlib, J., Reiter, A. (2020). Tyrosine Kinase Inhibitors in Systemic Mastocytosis. In: Akin, C. (eds) Mastocytosis. Springer, Cham. https://doi.org/10.1007/978-3-030-27820-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-27820-5_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-27822-9

  • Online ISBN: 978-3-030-27820-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation